Kezar Life Sciences
KZR was delisted on the 8th of May, 2026.
37 hedge funds and large institutions have $194M invested in Kezar Life Sciences in 2018 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 9 closing their positions.
122% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 9
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
58% more capital invested
Capital invested by funds: $123M → $194M (+$70.8M)
42% more funds holding
Funds holding: 26 → 37 (+11)
0.51% more ownership
Funds ownership: 4.23% → 4.74% (+0.51%)
38% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$17.9M |
| 2 |
BlackRock
New York
|
+$4.04M |
| 3 |
CI
Cowen Inc
New York
|
+$937K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$915K |
| 5 |
State Street
Boston,
Massachusetts
|
+$691K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$1.73M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$1.33M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.3M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$735K |
| 5 |
DIM
DC Investments Management
Mclean,
Virginia
|
-$585K |
KZR Hedge Fund Activity: Q3 2018 in Review
37 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Kezar Life Sciences (KZR) for Q3 2018, worth a combined $194M — up 58% from $123M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new KZR positions and 9 closed out — a net gain of 11 holders — while 5 added to existing stakes and 8 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $17.9M. The largest seller was Acuta Capital Partners, exiting entirely with an estimated $1.73M sold.
- 37 institutional investors held Kezar Life Sciences (KZR) as of Q3 2018, up from 26 in Q2 2018.
- Funds reported $194M of Kezar Life Sciences stock for Q3 2018, up 58% quarter-over-quarter.
- 20 funds opened new Kezar Life Sciences positions in Q3 2018 and 9 closed out, a net change of +11 holders.
- The largest Kezar Life Sciences buyer in Q3 2018 was Fidelity Investments, an estimated $17.9M added.
- The largest Kezar Life Sciences seller in Q3 2018 was Acuta Capital Partners, an estimated $1.73M sold.
Based on aggregated 13F filings for Q3 2018.